Cell cycle protein expression in AIDS-related and classical Kaposi’s sarcoma

Angela Hong

Submitted in total fulfilment of the requirements of the degree of

Doctor of Philosophy

Faculty of Medicine

The University of Sydney

2004
Statement of originality

The work presented in this thesis was carried out in the Departments of Radiation Oncology and Anatomical Pathology at Royal Prince Alfred Hospital, Sydney. All the experiments were designed, analysed and interpreted by the candidate, except where due acknowledgement is given in the text.

This thesis contains no material which has been submitted for any other degree at any university and complies with the stipulations set out for the degree of Doctor of Philosophy by the University of Sydney. It contains no material previously published by another researcher, except where due reference is made.

-----------------------------
Angela Hong
Faculty of Medicine
University of Sydney
New South Wales
Australia
# Table of contents

Statement of originality ........................................................................................................ ii  
Table of contents .................................................................................................................... ii  
List of tables and figures ....................................................................................................... vi  
Summary .................................................................................................................................. ix  
Acknowledgments ..................................................................................................................... xiii  
Publications and presentations ................................................................................................ xiv  
List of specific abbreviations .................................................................................................... xvii  
Chapter 1: Literature Review and Hypothesis ...................................................................... 2  
  1.1 Introduction ..................................................................................................................... 2  
  1.2 Clinical subtypes ............................................................................................................ 3  
    1.2.1 Classical Kaposi’s sarcoma ..................................................................................... 3  
    1.2.2 African Kaposi’s sarcoma ..................................................................................... 5  
    1.2.3 Kaposi’s sarcoma secondary to immunosuppressive treatment ....................... 6  
    1.2.4 AIDS-related Kaposi’s sarcoma ......................................................................... 8  
    1.2.5 Non AIDS-related homosexual related Kaposi’s sarcoma ................................ 12  
  1.3 Treatment of Kaposi’s sarcoma ....................................................................................... 12  
    1.3.1 Classical Kaposi’s sarcoma .................................................................................... 12  
    1.3.2 Immunosuppressive treatment related Kaposi’s sarcoma ..................................... 13  
    1.3.3 AIDS-related Kaposi’s sarcoma ......................................................................... 14  
  1.4 Histopathology ............................................................................................................... 18  
  1.5 Initiation and development of Kaposi’s sarcoma ........................................................... 21  
  1.6 Natural history of Kaposi’s sarcoma .............................................................................. 22  
  1.7 Role of human herpes virus 8 in the development of Kaposi’s sarcoma ..................... 25  
    1.7.1 Epidemiology and transmission of HHV8 ........................................................... 25  
    1.7.2 Detection of HHV8 ............................................................................................. 27  
    1.7.3 Molecular genetics of HHV8 in neoplasia ............................................................ 28  
    1.7.4 HHV8 infection and Kaposi’s sarcoma ................................................................. 31  
  1.8 Role of HIV in the development of Kaposi’s sarcoma ................................................. 34
1.9 Cell cycle regulation ................................................................. 35
1.10 Hypothesis and aims ............................................................. 40

Chapter 2: Methods and Materials .............................................. 45

2.1 Clinico-pathological study ......................................................... 45
2.2 Fixation of specimens ............................................................... 47
2.3 Haematoxylin and eosin staining ................................................. 48
2.4 Immunohistochemistry ............................................................... 49
2.5 Statistical analysis ................................................................. 53
2.6 Detection of HHV8 in Kaposi’s sarcoma cell culture .................. 53

Chapter 3: Clinico-pathological Analysis ......................................... 56

3.1 Histopathology and classification of Kaposi’s sarcoma lesions at different stages of development .................................................. 56
3.2 Distribution of lesions ............................................................. 57
3.3 HIV status and histopathological features in Kaposi’s sarcoma ...... 58
3.4 HIV status and relationship to clinical features in patients with KS .... 59
3.5 Incidence of Kaposi’s sarcoma over the ten-year period (1990-1999) ... 60
3.6 Discussion ........................................................................ 64

Chapter 4: Detection of HHV8 in Kaposi’s sarcoma ....................... 72

4.1 Background ............................................................................. 72
4.2 Methods ................................................................................. 72
4.3 Results .................................................................................. 73
4.4 Discussion ........................................................................ 78

Chapter 5: Ki-67 expression in Kaposi’s sarcoma ............................. 82

5.1 Introduction ........................................................................ 82
5.2 Methods ............................................................................. 83
5.3 Results ................................................................................. 83
Chapter 6: Expression of the Rb protein and cell cycle proteins acting upstream of Rb in Kaposi’s sarcoma

6.1 Background

6.2 Methods

6.3 Results

6.4 Discussion

Chapter 7: The role of mitotic cyclins in Kaposi’s sarcoma - Cyclin A and p34^cdc2 expression in Kaposi’s sarcoma

7.1 Background

7.2 Methods

7.3 Results

7.4 Discussion

Chapter 8: Exploring the p53 pathway in Kaposi’s sarcoma - Cyclin G1 and mutant p53 expression in Kaposi’s sarcoma

8.1 Background

8.2 Methods

8.3 Results

8.4 Discussion

Chapter 9: p57 and p27 expression in Kaposi’s sarcoma

9.1 Introduction

9.2 Methods

9.3 Results

9.3 Discussion

Chapter 10: Concluding remarks

10.1 Introduction

10.2 Conclusions and significance of the findings in this thesis
10.3 Summary of the findings in this thesis ................................................ 175
Appendix 1 Protocol for immunohistochemistry ........................................ 182
Appendix 2: Raw data of clinicopathological parameters .......................... 186
Appendix 3: Raw data of immunohistochemistry results ........................... 189
References ..................................................................................................... 191
List of tables and figures

Figure 1.1 Classical Kaposi’s sarcoma on the foot of a 66-year-old man of Mediterranean extraction ................................................................. 5

Figure 1.2 CT scan of the chest showing pulmonary infiltration with Kaposi’s sarcoma in a HIV positive male patient ...................................................... 11

Figure 1.3 Extensive Kaposi’s sarcoma in lower legs causing ulceration and oedema in a HIV positive male patient ....................................................... 11

Figure 1.4 Regulation of the cell cycle by cell cycle proteins....................... 39

Table 2.1 Demographic and clinical data ......................................................... 46

Table 2.2 Pathological data .............................................................................. 46

Figure 2.1 Reaction of Haematoxylin dye ......................................................... 48

Figure 2.2 Avidin-biotin complex method ......................................................... 50

Table 2.3 List of primary antibody tested .......................................................... 52

Table 3.1 Anatomical distribution of cutaneous lesions .................................... 57

Table 3.2 Anatomical distribution of non-cutaneous lesions ............................. 57

Figure 3.1 Light microscopy of a patch stage Kaposi’s sarcoma (H&E, x40) ... 61

Figure 3.2 Light microscopy of a plaque stage Kaposi’s sarcoma (H&E, x40) . 61

Figure 3.3 Light microscopy of a nodular Kaposi’s sarcoma (H&E, x20) ........ 62

Figure 3.4 Light microscopy of a nodular Kaposi’s sarcoma (H&E, x40) ........ 62

Figure 3.5 High power view of a nodular Kaposi’s sarcoma (H&E, x400) ........ 63

Table 3.3 Histological subtypes of Kaposi’s sarcoma and correlation with pathological features .................................................................................. 68

Table 3.4 Histological subtypes of Kaposi’s sarcoma and correlation with clinical features .................................................................................................. 70

Figure 4.1 Positive HHV8 staining in a patch stage lesion (x400) ................. 75

Figure 4.2 Positive HHV8 staining in a plaque stage lesion (x400) ............... 75

Figure 4.3 Positive HHV8 staining in a nodular lesion (x400) ....................... 76

Table 4.1: Detection of HHV8 in Kaposi’s sarcoma ........................................ 76
Table 4.2: HHV8 expression in Kaposi’s sarcoma and the correlation with clinico-pathological data .................................................................................................................................. 77

Figure 5.1 Ki-67 staining score in classical and AIDS-related lesions

Figure 5.2 Ki-67 staining score in different histological subtypes .............................................. 84

Figure 5.2 Ki-67 staining score in different histological subtypes ..................................... 85

Table 5.1 Summary of studies in the current literature on the prognostic value of Ki-67 in malignancy .......................................................................................................................... 90

Figure 6.1 Positive staining of cyclin D1 in a patch stage lesion (x400) ............ 99

Figure 6.2 Positive staining of cyclin D1 in a nodular stage lesion (x400) ...... 100

Figure 6.3 Positive staining of Rb in a nodular lesion (x400) ......................... 100

Table 6.1 Expression of cyclin D1 in different histological subtypes ....................... 101

Table 6.2 Expression of cyclin D1 in nodular stage lesions ........................................ 101

Table 6.3 Cyclin D1 expression and correlation with clinicopathological data ........ 102

Table 6.4 Expression of Rb in Kaposi’s sarcoma .................................................. 103

Table 6.5 Expression of p16 in Kaposi’s sarcoma ............................................. 104

Figure 7.1 Lack of cyclin A expression in a patch lesion (x 400) .................. 125

Figure 7.2 Cyclin A expression in several cells in a nodular KS (x 200) ........ 125

Figure 7.3 Positive p34\textsuperscript{cdc2} staining in a patch lesion (x 200) .............. 126

Figure 7.4 High power view of lesional cells positive for p34\textsuperscript{cdc2} in a patch lesion (x 400) ........................................................................................................ 126

Table 7.1 Expression of cyclin A in Kaposi’s sarcoma ........................................ 127

Table 7.2: Cyclin A expression and correlation with clinico-pathological data ........ 128

Figure 7.5 Ki-67 staining in cyclin A positive and cyclin A negative lesions ... 129

Table 7.3 p34\textsuperscript{cdc2} expression in Kaposi’s sarcoma ...................................... 129

Figure 8.1 Lack of cyclin G1 staining in a patch stage KS lesion (x200) ...... 140

Figure 8.2 Positive staining of cyclin G1 in a nodular lesion (x400) .............. 140

Figure 8.3 Lack of mutant p53 staining in a patch stage KS lesion (x200) ..... 141

Figure 8.4 Positive staining of mutant p53 in a nodular lesion (x400) ........... 141
Table 8.1: Cyclin G1 expression according to clinical parameters .......... 142
Table 8.2: Mutant p53 expression according to clinical parameters .......... 143
Table 9.1 p27 expression in different stages of Kaposi’s sarcoma .......... 155
Table 9.2 p27 expression and correlation with clinico-pathological features .. 156
Table 10.1 Summary of findings ................................................................. 178
Table 10.2: Correlation of cell cycle regulators in the cyclin D1 positive cases ................................................................. 179
Table 10.3 Correlation between cell cycle protein expression and HHV8 status ................................................................. 180
Fig.10.1 Summary of the key events in the pathogenesis of Kaposi’s sarcoma ................................................................. 181
Summary

Kaposi’s sarcoma (KS) is a peculiar vascular neoplasm that occurs mainly in elderly Mediterranean men and patients with acquired immunodeficiency syndrome (AIDS). The current literature indicates that KS is initiated by the human herpes virus 8 (HHV8) as a reactive polyclonal process but with deregulation of oncogene and tumour suppressor genes, it can progress to a true malignancy with monoclonality. Clinically, classical KS often presents as an indolent disease affecting mainly the lower extremities whereas AIDS-related KS has no site predilection and can progress rapidly with systemic involvement. Histologically, KS can be classified into patch, plaque and nodular stages. Interestingly, classical and AIDS-related KS are indistinguishable histologically and this suggests that AIDS-related KS and classical KS might be initiated by a common aetiology but given their different clinical courses, they may progress through different mechanisms. In view of the importance of the cell cycle proteins in the development and progression of many human malignancies, this thesis aims to examine the role of these proteins in the progression of the two main clinical subtypes of KS.

The cell cycle protein expressions in a cohort of 47 patients with KS with well-documented clinical and histological features were studied. Using a monclonal antibody against the latent nuclear antigen-1 molecule of HHV8, HHV8 was detected in 78% of the cases. The more advanced nodular lesions were found to have a higher level of proliferative activity as measured by the proliferation
marker, Ki-67. This suggests it is valid to use the histological specimens as a tumour progression model of KS.

The role of the Rb/cyclin D1/p16 pathway was examined. The more advanced nodular stage KS lesions were more likely to be positive for cyclin D1, suggesting that cyclin D1 is important in the progression from patch stage to nodular stage. p16 acts as a tumour suppressor and it has an inhibitory effect on cyclin D1. The p16 expression rate was low in early stage KS but high in the more advanced lesions. It seems that reduced p16 expression occurs early in KS and may be important in its development. The rate of Rb expression, on the other hand, did not differ significantly among the histological subtypes. The results revealed the significant role of the Rb/cyclin D1/p16 pathway in the progression of KS.

Of the mitotic cyclins examined, cyclin A expression was correlated with the advanced tumor stage. The rate of p34<sup>cdc2</sup> expression was high in the lesions and there was no correlation with histological stage. This suggests that p34<sup>cdc2</sup> is important in the early development of the tumour but not necessarily in its progression.

Along the p53-apoptotic pathway, mutant p53 expression was significantly more common in the nodular stage. The cyclin G1 (a protooncogene, one of the target genes of p53) expression also paralleled that of mutant p53 with the majority of the KS lesions showing cyclin G1 expression and significant
correlation between advanced histological stage and increasing rate of cyclin G1 expression. These findings suggest that progression along the p53 pathway may be important in the advanced stage development of KS. On the other hand, expression of the CDK inhibitor, p27, a protein that normally negatively regulates cyclin G1, was reduced in nodular KS. These findings suggest that some KS lesions may progress through a deregulated or abnormal p53 pathway.

There were correlations between cyclin D1, cyclin A, cyclin G1, mutant p53 and negative HIV status. The findings suggest that components of both the Rb/cyclin D1/p16 and p53-apoptotic pathways are important in the progression of classical KS.

Rb protein was the only cell cycle protein whose rate of expression correlated significantly with HHV8 status in KS. The majority of HHV8 positive lesions were also positive for Rb protein, unlike HHV8 negative lesions. This suggests that some of the HHV8 negative lesions can progress through a defective Rb pathway whereas the role of Rb in the progression may not be as important in the HHV8 positive lesions. This was an unexpected finding given that one of the postulated mechanisms of tumour initiation by the HHV8 virus is via the viral cyclin it produces. The viral cyclin produced by HHV8 acts through the Rb pathway much the same as cyclin D1 and one would have expected that HHV8 positive cases are less likely to be positive for the Rb protein.
In summary, the majority of the KS lesions examined in this thesis show HHV8 infection. The Rb/cyclin D1/p16 pathway appears to be important in the progression of the different stages of KS and expression of the proteins involved in the p53 pathway were found to be important in the advanced stages of the development of KS. There were differential expressions of cell cycle proteins between AIDS-related and classical KS, and between HHV8 positive and HHV8 negative lesions. The findings also provided some clues to the possible mechanisms of development in KS lesions that were not initiated by HHV8.
Acknowledgments

This research has been the product of work performed in the Departments of Anatomical Pathology and Radiation Oncology at Royal Prince Alfred Hospital. The staff who have helped with the preparation of the specimens and supported the research are gratefully acknowledged.

My supervisor, Professor Soon Lee, has provided me with immense guidance and encouragement for continued pursuit of this thesis.

Special acknowledgement is made to my mentor, Professor Graham Stevens, who guided me through my clinical training and has continued to advise on my career development.

To my husband, Andrew, I am grateful for his love, encouragement and support during my candidature.
Publications and presentations


5. Hong A, Sarris M, Lee CS. Expression of cyclin G1, mutant p53, p16 and retinoblastoma protein in classical and AIDS-related Kaposi’s sarcoma. (Submitted for publication)

6. Hong A, Davies S, Lee CS. Cyclin A and Ki-67 expression in AIDS-related and classical Kaposi’s sarcoma (submitted for publication)
Abstract Publications:


Presentations arising from this thesis:

1. Hong A, Stevens G, Lee CS (2000). Cyclin D1 expression in AIDS-related and endemic Kaposi’s sarcoma. Poster presentation at the 26th Annual Scientific Meeting of the International Academy of Pathology

2. Hong A, Stevens G, Lee CS (2000). Kaposi’s sarcoma: A clinicopathological analysis of 42 patients. Poster presentation at the 26th Annual Scientific Meeting of International Academy of Pathology

4. Hong A, Sarris M, Lee CS (2001). Overexpression of cyclin A in Kaposi’s sarcoma. Poster presentation at the 27th Annual Scientific Meeting of International Academy of Pathology


6. Hong A, Sarris M, Lee CS (2002). Expression of the cyclin dependent kinase, p34cdc2, occurs early in the development of Kaposi’s sarcoma. Poster presentation at the 28th Annual Scientific Meeting of International Academy of Pathology
<table>
<thead>
<tr>
<th>Abbreviation</th>
<th>Full Form</th>
</tr>
</thead>
<tbody>
<tr>
<td>Avidin Biotin Complex</td>
<td>ABC</td>
</tr>
<tr>
<td>Acquired Immunodeficiency Syndrome</td>
<td>AIDS</td>
</tr>
<tr>
<td>Epstein Barr Virus</td>
<td>EBV</td>
</tr>
<tr>
<td>Gray</td>
<td>Gy</td>
</tr>
<tr>
<td>Human Immunodeficiency Virus</td>
<td>HIV</td>
</tr>
<tr>
<td>Human Herpes Virus 8</td>
<td>HHV8</td>
</tr>
<tr>
<td>Immunoperoxidase</td>
<td>IPX</td>
</tr>
<tr>
<td>Kaposi’s Sarcoma</td>
<td>KS</td>
</tr>
<tr>
<td>Retinoblastoma</td>
<td>Rb</td>
</tr>
</tbody>
</table>